{"id":"NCT02106832","sponsor":"Bayer","briefTitle":"Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","officialTitle":"Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-30","primaryCompletion":"2016-09-13","completion":"2016-10-19","firstPosted":"2014-04-08","resultsPosted":"2017-09-01","lastUpdate":"2017-10-02"},"enrollment":521,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bronchiectasis"],"interventions":[{"type":"DRUG","name":"Ciprofloxacin (BAYQ3939) dry powder for inhalation","otherNames":[]},{"type":"DRUG","name":"Ciprofloxacin (BAYQ3939) dry powder for inhalation","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ciprofloxacin DPI 28 Days on/off (Cipro 28)","type":"EXPERIMENTAL"},{"label":"Ciprofloxacin DPI 14 Days on/off (Cipro 14)","type":"EXPERIMENTAL"},{"label":"Placebo 28 Days on/off (Placebo 28)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo 14 Days on/off (Placebo 14)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.","primaryOutcome":{"measure":"Time to First Exacerbation Event Within 48 Weeks - Cipro 28 vs. Pooled Placebo","timeFrame":"Up to Week 48","effectByArm":[{"arm":"Ciprofloxacin DPI 28 Days on/Off (Cipro 28)","deltaMin":null,"sd":null},{"arm":"Pooled Placebo","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0511"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":207,"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","China","Czechia","Germany","Hong Kong","Latvia","Lithuania","Netherlands","Philippines","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Taiwan","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["29371384","28495619"],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":171},"commonTop":["Haemoptysis","Nasopharyngitis","Headache","Upper respiratory tract infection","Cough"]}}